New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
23:40 EDTSLE, GLD, KORS, WPRT, DRI, CMG, RNDY, AUQ, P, ESRX, STO, BEAM, COV, AGN, CELG, HD, TSCO, TITN, SHW, CHKJim Cramer's "Mad Money"
Jim Cramer said, "2012 is no longer about global economic crisis, it's about buying stock in the companies you love." Cramer said he's no longer sweating the details of every story that hits the news wires. Because the big-money players, those who would sell on every bit of negative news, are simply no longer a part of this market. They have been replaced by good old-fashioned individual investors. When companies break up, investors win, Cramer reminded viewers, as he highlighted yet another corporate breakup story, Sara Lee (SLE). He said that shares of Sara Lee should follow in the footsteps of Beam (BEAM) and Covidien (COV), two other breakup stocks, which headed markedly higher. Sara Lee is offering a $3-a-share special dividend to shareholders when the breakup occurs. Additionally, recent analysis of Sara Lee's various components values the stock 22% higher than where it trades today. Sara Lee plans to update shareholders on its progress at an investors meeting on June 5. Investing in Sara Lee will be a slow climb, said Cramer, which is why he would use recent weakness in the stock to get in at attractive prices. Continuing with his week-long series of great American growth stocks, Cramer turned the spotlight onto Allergan (AGN). It is not only a health care company that treats eye problems and migraines, but it is also a leader in medical aesthetics, including Botox and great implants. Cramer said that Allergan has multiple years of growth ahead of it. Its end markets are huge. Also, Allergan is highly competitive in every arena in which it enters and the company pays a tiny dividend. Shares trade for just 19x earnings and the company has a 14% long-term growth rate. Giving investors another great American growth stock, Cramer also highlighted Celgene (CELG), another stock just off its 52-week high. Celgene has one of the fastest growth rates in its sector, said Cramer, and also huge market potential as a host of new products and new applications for existing products are chugging toward FDA approval. Internationally, the company is a powerhouse. Cramer said that while Celgene is unlikely to offer a dividend anytime soon, the company has done a few well-timed stock buybacks to reward shareholders. Celgene sports a rock-solid balance sheet. Celgene trades at just 13.8x next year's earnings, despite the company's 24% growth rate. NO HUDDLE OFFENSE: Cramer said that the tailwinds are all lining up for a great quarter at Home Depot (HD), and he would be a buyer of the stock, even up near its 52-week high. Case-in-point: Tractor Supply (TSCO) announced sales that are double what analysts are expecting and Titan Machinery (TITN) pre-announced strong earnings, followed by Sherwin-Williams (SHW) announcing sales up by 20%. LIGHTNING ROUND: (Bullish) STO; ESRX; GLD; KORS; WPRT; DRI; CMG; RNDY. (Bearish) AUQ; P; CHK. Reference Link
News For SLE;BEAM;COV;AGN;CELG;HD;TSCO;TITN;SHW;STO;ESRX;GLD;KORS;WPRT;DRI;CMG;RNDY;AUQ;P;CHK From The Last 14 Days
Check below for free stories on SLE;BEAM;COV;AGN;CELG;HD;TSCO;TITN;SHW;STO;ESRX;GLD;KORS;WPRT;DRI;CMG;RNDY;AUQ;P;CHK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 9, 2014
18:09 EDTHDLumber Liquidators plummets after cutting full-year outlook
Shares of hardwood flooring and accessories retailer Lumber Liquidators (LL) are sinking in after-hours trading after the company cut its fiscal 2014 outlook. It also forecast second quarter results far below analysts' consensus estimates. WHAT'S NEW: After the bell, Lumber Liquidators forecast Q2 earnings per share of 59c-61c, far short of the consensus estimate of 90c. Q2 sales came in at $263.1M, also well below estimates of $303.21M. Comparable store sales decreased 7.1% for the quarter, and the company expects gross margin in Q2 to contract year over year. WHAT'S NOTABLE: Due to the weak Q2 performance, the company cut its FY14 EPS view to $2.65-$3.00 from $3.25-$3.60, versus consensus of $3.34. It also lowered its FY14 revenue outlook to $1.05B-$1.1B from $1.15B-$1.2B, versus consensus of $1.16B. It forecast comparable store net sales in the low single digits, either positive or negative, compared to its previous view of an increase ranging from mid to high single digits. It sees opening a total of 33 to 37 new store locations in the expanded showroom format, down from the previous view of 35 to 40. CEO Lynch said, "A number of the factors weighing on our second quarter results are likely to continue in the second half of 2014. While we believe the third quarter may be weaker than we originally anticipated, we have a strong sense of urgency and we expect to regain traction to deliver operating margin expansion in the second half and in coming years." PRICE ACTION: In evening trading, Lumber Liquidators fell $13.52, or 19.2%, to $56.90 on heavy trading volume. OTHERS TO WATCH: Other companies in the flooring space include Tile Shop (TTS), down 5%, Home Depot (HD), down 1%, and Lowe's (LOW), down 1.8%.
16:25 EDTCELGCelgene reports 11.9% passive stake in GlobeImmune
Subscribe for More Information
16:06 EDTTSCOTractor Supply now sees FY14 results at low end of guidance range
Based upon its Q2 results, the company anticipates FY14 results will be at the low end of the previously provided ranges. Sees FY14 revenue $5.62B-$5.7B, consensus $5.67B. Sees FY14 EPS $2.54-$2.62, consensus $2.62. Sees FY14 comparable store sales up 2.5%-4.0%.
16:04 EDTTSCOTractor Supply now sees FY14 results at low end of guidance range
Subscribe for More Information
16:04 EDTTSCOTractor Supply sees Q2 EPS 94c-95c , consensus $1.02
Subscribe for More Information
11:57 EDTCELGCelgene shares higher despite missing primary endpoint in Otezla trial
Subscribe for More Information
10:25 EDTCHKChesapeake price target raised to $33 from $30 at JPMorgan
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
09:13 EDTCELGOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTCELGCelgene says OTEZLA did not achieve primary endpoint in Phase III trial
Celgene Corporation announced results of its phase III POSTURE study evaluating OTEZLA, the companyís oral, selective inhibitor of phosphodiesterase 4, in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing. An independent data monitoring committee recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points. The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new safety signals were observed. The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented at an upcoming medical meeting. These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with ankylosing spondylitis in any country.
07:01 EDTKORSMichael Kors names Mark Brashear as president of Men's, effective July 7
Subscribe for More Information
06:19 EDTAGNAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackmanís hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
05:59 EDTGLDSPDR Gold Trust overall implied volatility at 13; 26-week average is 15
Subscribe for More Information
July 8, 2014
09:05 EDTDRIDarden announces new national restaurant remodel design
Subscribe for More Information
07:39 EDTCHKUBS to hold a mini-conference
Subscribe for More Information
07:04 EDTCOVCovidien added to short-term buy list at Deutsche Bank
Subscribe for More Information
06:53 EDTKORSMichael Kors re-launch of eyewear a multi-year catalyst, says Piper Jaffray
Piper Jaffray believes the recently signed 10-year license agreement between Michael Kors (KORS) and Luxottica (LUX) represents a multi-year opportunity for both companies. After meeting with Luxottica, Piper believes the company's goal of $100M in wholesale sales in three years could prove conservative given the growing appeal for the Michael Kors brand. The firm views eyewear as another comp drive for Michael Kors and a multi-year catalyst for the company. It keeps an Overweight rating on the stock with a $115 price target.
05:50 EDTGLDSPDR Gold Trust overall implied volatility at 13; 26-week average is 15
Subscribe for More Information
05:48 EDTKORSStocks with implied volatility movement; NNG KORS
Subscribe for More Information
05:35 EDTSTOTechnip awarded renewal of framework agreement by Statoil, Exxon Mobil, Gassco
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use